Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management

Stevens‐Johnson syndrome and toxic epidermal necrolysis‐like reactions to checkpoint inhibitors: a systematic review

(2020) Nolan J. Maloney et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast

(2019) Davide Fattore et al.   EUROPEAN JOURNAL OF CANCER

Clinical epidemiology and treatment of lichen planus: a retrospective review of two tertiary care centers

(2019) Zachary Schwager et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy

(2019) Blake M. Warner et al.   ONCOLOGIST

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy

(2019) Daniel Johnson et al.   Cancer Immunology Research

Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review

(2019) Vignesh Ravi et al.   Dermatologic Therapy

Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer

(2019) Giulia Galli et al.   TUMORI

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

(2019) Fan Bai et al.   Journal of Immunology Research

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

(2019) David J. Pinato et al.   JAMA Oncology

Vasculitis associated with immune checkpoint inhibitors—a systematic review

(2018) Anisha Daxini et al.   CLINICAL RHEUMATOLOGY

A Case of Advanced Lung Adenocarcinoma with Nvolumab-associated Dermatomyositis

(2018) Fumiaki Kudo et al.   INTERNAL MEDICINE

Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid

(2018) Alyson V. Ridpath et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors

(2018) Adriana T. Lopez et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review

(2018) Koya Obara et al.   JOURNAL OF DERMATOLOGY

Bullous Pemphigoid–like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab

(2018) Amalia Anastasopoulou et al.   JOURNAL OF IMMUNOTHERAPY

Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study

(2018) Charles Kyung Min Lee et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy

(2018) Jacob Siegel et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies

(2018) Chun-Bing Chen et al.   Cancer Management and Research

Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients

(2018) Michael T. Tetzlaff et al.   Journal for ImmunoTherapy of Cancer

Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series

(2018) Alessandro Tomelleri et al.   European Journal of Internal Medicine

Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy

(2018) Marie Donaldson et al.   Frontiers in Oncology

Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature

(2018) Noa Kremer et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect

(2018) Xavier Grimaux et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institutional, retrospective analysis with stratification of reactions by toxicity and implications for management

(2018) Emily Coleman et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Pembrolizumab-induced Stevens–Johnson syndrome in non-melanoma patients

(2017) Stephanie Saw et al.   EUROPEAN JOURNAL OF CANCER

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy

(2017) Karina L. Vivar et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo

(2017) Maiana Larsabal et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis

(2017) Julia Dai et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology

(2017) J. P. Bandino et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial

(2017) Hywel C Williams et al.   LANCET

Scleroderma Induced by Pembrolizumab: A Case Series

(2017) Naiara S. Barbosa et al.   MAYO CLINIC PROCEEDINGS

Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome

(2017) Sayeef Mirza et al.   MELANOMA RESEARCH

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade

(2017) Khashayar Esfahani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis

(2017) Hui Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid

(2017) Laura Sowerby et al.   JAMA Dermatology

Pembrolizumab-Induced Extensive Panniculitis and Nevus Regression

(2017) Sara Burillo-Martinez et al.   JAMA Dermatology

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

(2017) Vivek Kumar et al.   Frontiers in Pharmacology

Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma

(2016) N Matsumura et al.   ACTA DERMATO-VENEREOLOGICA

Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

(2016) S. Cousin et al.   ANNALS OF ONCOLOGY

Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma

(2016) Sagun Parakh et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma

(2016) François-Xavier Danlos et al.   CHEST

Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy

(2016) Simone M. Goldinger et al.   CLINICAL CANCER RESEARCH

Hypertrophic lichen planus - successful treatment with acitretin

(2016) Ali Alamri et al.   Dermatologic Therapy

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

(2016) V.R. Belum et al.   EUROPEAN JOURNAL OF CANCER

Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment

(2016) Nicholas Gulati et al.   EXPERIMENTAL DERMATOLOGY

Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy

(2016) Kurt B. Schaberg et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions

(2016) George Jour et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study

(2016) Yasuhiro Nakamura et al.   JOURNAL OF DERMATOLOGY

Toxic Epidermal Necrolysis–like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma

(2016) Namrata Nayar et al.   JOURNAL OF IMMUNOTHERAPY

Anti-PD1-induced psoriasis: a study of 21 patients

(2016) J. Bonigen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies

(2016) Shelley J.E. Hwang et al.   MELANOMA RESEARCH

Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer

(2016) Sarah Law-Ping-Man et al.   RHEUMATOLOGY

Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma

(2016) Mariam B. Totonchy et al.   JAMA Dermatology

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy

(2016) Veronica J. Shi et al.   JAMA Dermatology

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

(2016) Camille Hua et al.   JAMA Dermatology

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

(2016) J. Naidoo et al.   Cancer Immunology Research

Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid

(2016) Kristen M. Beck et al.   Journal for ImmunoTherapy of Cancer

Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy

(2016) Viktor H. Koelzer et al.   Journal for ImmunoTherapy of Cancer

Treatments for Cutaneous Lichen Planus: A Systematic Review and Meta-Analysis

(2015) Lihi Atzmony et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports

(2015) Taku Fujimura et al.   JOURNAL OF DERMATOLOGY

Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma

(2015) Y. Kato et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab

(2015) Giuliana Carlos et al.   MELANOMA RESEARCH

T follicular regulatory cells in the regulation of B cell responses

(2015) Peter T. Sage et al.   TRENDS IN IMMUNOLOGY

Drug-Associated Dermatomyositis Following Ipilimumab Therapy

(2015) Shirwa Sheik Ali et al.   JAMA Dermatology

Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma

(2015) Mikio Ohtsuka et al.   JAMA Dermatology

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

(2015) Martina Sanlorenzo et al.   JAMA Dermatology

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

(2014) P.H. Schafer et al.   CELLULAR SIGNALLING

Omalizumab therapy for bullous pemphigoid

(2014) Kenneth K. Yu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Drug-induced pemphigoid: a review of the literature

(2014) P.G. Stavropoulos et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Lichenoid Mucosal Reaction to Rituximab

(2014) M. Kuten-Shorrer et al.   ONCOLOGIST

Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy

(2014) R. W. Joseph et al.   Cancer Immunology Research

Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study

(2013) S.H. Kardaun et al.   BRITISH JOURNAL OF DERMATOLOGY

The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis

(2013) Kira Minkis et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Toxic epidermal necrolysis

(2013) Robert A. Schwartz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

(2013) Caroline J. Voskens et al.   PLoS One

PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

(2012) John Dulos et al.   JOURNAL OF IMMUNOTHERAPY

An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: A case series

(2012) Joan Paul et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Carcinogenic risks of Psoralen UV-A therapy and Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review

(2012) E. Archier et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The DRESS Syndrome: A Literature Review

(2011) Patrice Cacoub et al.   AMERICAN JOURNAL OF MEDICINE

Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: An update

(2011) Annette Czernik et al.   AUTOIMMUNITY

Human TH17 Cells Are Long-Lived Effector Memory Cells

(2011) I. Kryczek et al.   Science Translational Medicine

Retinoid pathway and cancer therapeutics

(2010) Nathan Bushue et al.   ADVANCED DRUG DELIVERY REVIEWS

Danger Signs in Drug Hypersensitivity

(2010) Kathrin Scherer et al.   MEDICAL CLINICS OF NORTH AMERICA

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endogenous IL-17 contributes to reduced tumor growth and metastasis

(2009) I. Kryczek et al.   BLOOD

Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments

(2009) I. Kryczek et al.   BLOOD

Lichen planus–like eruptions: An emerging side effect of tumor necrosis factor-α antagonists

(2009) Adam Asarch et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Treatment of cutaneous lichen planus with thalidomide

(2008) A. K. A. Moura et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study

(2007) Maja Mockenhaupt et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY